Terms: = Ovarian cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
473 results:
1. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board.
Horn IP; Zakas AL; Smith-Simmer KJ; Birkeland LE; Sundstrom R; Burkard ME; Weiss JM
JCO Precis Oncol; 2024 May; 8():e2300466. PubMed ID: 38810171
[TBL] [Abstract] [Full Text] [Related]
2. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF; Manning-Geist BL; Zhou Q; Soumerai T; Holland A; Da Cruz Paula A; Green H; Ozsoy MA; Iasonos A; Hollmann T; Leitao MM; Mueller JJ; Makker V; Tew WP; O'Cearbhaill RE; Liu YL; Rubinstein MM; Troso-Sandoval T; Lichtman SM; Schram A; Kyi C; Grisham RN; Causa Andrieu P; Wherry EJ; Aghajanian C; Weigelt B; Hensley ML; Zamarin D
Nat Med; 2024 May; 30(5):1330-1338. PubMed ID: 38653864
[TBL] [Abstract] [Full Text] [Related]
3. The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.
Liu Y; Geng F; Zhang H; Xue J; Chu R
World J Surg Oncol; 2024 Jan; 22(1):37. PubMed ID: 38287354
[TBL] [Abstract] [Full Text] [Related]
4. Reduced healthcare access contributes to delay of care in endometrial cancer.
Fife AJ; Najor AJ; Aspir TB; Haines KE; Vilardo NA; Isani SS; Cowan M; Gressel GM; Ye KQ; Nevadunsky NS; Kuo DY; Lin KY
Gynecol Oncol; 2024 Mar; 182():115-120. PubMed ID: 38262233
[TBL] [Abstract] [Full Text] [Related]
5. EGFR, HLA-G, CD70, c-met, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
Vo D; Liu Y; Sood AK; Rezvani K; Jazaeri AA; Liu J
Cancer Biomark; 2024; 39(4):289-298. PubMed ID: 38250760
[TBL] [Abstract] [Full Text] [Related]
6. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
How JA; Legarreta AF; Handley KF; Fellman B; Foster KI; Glassman D; Vuttaradhi VK; Brodsky AL; Lawson B; Frumovitz M; Westin SN; Ramondetta LM; Gershenson DM; Sood AK; Hillman RT
Am J Obstet Gynecol; 2024 May; 230(5):544.e1-544.e13. PubMed ID: 38191019
[TBL] [Abstract] [Full Text] [Related]
7. Impact of ovary-sparing treatment planning on plan quality, treatment time and gamma passing rates in intensity-modulated radiotherapy for stage I/II cervical cancer.
Huang Y; Qin T; Yang M; Liu Z
Medicine (Baltimore); 2023 Dec; 102(50):e36373. PubMed ID: 38115303
[TBL] [Abstract] [Full Text] [Related]
8. Rationale and methodologic Approach for Assessing ovarian cancer treatment and Gynecologic Oncologist Involvement in the Midwest Region of the United States.
Ng D; Ross W; Traverso-Ortiz M; Rim SH; Wike JM; Moore AR;
J Registry Manag; 2023; 50(3):85-91. PubMed ID: 37941740
[TBL] [Abstract] [Full Text] [Related]
9. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Randall LM; O'Malley DM; Monk BJ; Coleman RL; Gaillard S; Adams S; Duska LR; Dalton H; Holloway RW; Huang M; Chon HS; Cloven NG; ElNaggar AC; O'Cearbhaill RE; Waggoner S; Tarkar A; Striha A; Nelsen LM; Baines A; Samnotra V; Konstantinopoulos PA
Gynecol Oncol; 2023 Nov; 178():161-169. PubMed ID: 37890345
[TBL] [Abstract] [Full Text] [Related]
10. Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC).
Kim YB; Byun HK; Wee CW; Kim H; Kim S; Yang G; Kim J; Park SJ; Lee JY
BMC Cancer; 2023 Oct; 23(1):1014. PubMed ID: 37864152
[TBL] [Abstract] [Full Text] [Related]
11. treatment of Recurrent Low-grade Serous ovarian cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract] [Full Text] [Related]
12. All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer.
Jorgensen K; Denham C; Kanbergs A; Wu CF; Nitecki R; Agusti N; Meernik C; Melamed A; Rauh-Hain JA
Gynecol Oncol; 2023 Nov; 178():60-68. PubMed ID: 37801736
[TBL] [Abstract] [Full Text] [Related]
13. Dose reduction of olaparib in older patients: Insights from an analysis of a National Database in Japan.
Sato M; Goto T
J Obstet Gynaecol Res; 2023 Dec; 49(12):2889-2893. PubMed ID: 37786354
[TBL] [Abstract] [Full Text] [Related]
14. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial cancer.
Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; Mirza MR; Makker V;
J Clin Oncol; 2023 Dec; 41(35):5400-5410. PubMed ID: 37669480
[TBL] [Abstract] [Full Text] [Related]
15. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
J Gynecol Oncol; 2023 Sep; 34(5):e85. PubMed ID: 37593813
[TBL] [Abstract] [Full Text] [Related]
16. A Systematic Review of Surgical Management Strategies in the treatment of Peritoneal Carcinomatosis of Neuroendocrine Origin.
Fallows M; Samant A; Wilson H; Mirnezami R
Curr Oncol; 2023 Jul; 30(7):6316-6329. PubMed ID: 37504326
[TBL] [Abstract] [Full Text] [Related]
17. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract] [Full Text] [Related]
18. Interventions to support decision making in people considering germline genetic testing for BRCA 1/2 pathogenic and likely pathogenic variants: A scoping review.
Pozzar RA; Seven M
J Genet Couns; 2024 Apr; 33(2):392-401. PubMed ID: 37328917
[TBL] [Abstract] [Full Text] [Related]
19. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Hagio K; Kikuchi J; Takada K; Tanabe H; Sugiyama M; Ohhara Y; Amano T; Yuki S; Komatsu Y; Osawa T; Hatanaka KC; Hatanaka Y; Mitamura T; Yabe I; Matsuno Y; Manabe A; Sakurai A; Ishiguro A; Takahashi M; Yokouchi H; Naruse H; Mizukami Y; Dosaka-Akita H; Kinoshita I
Cancer Sci; 2023 Aug; 114(8):3385-3395. PubMed ID: 37208840
[TBL] [Abstract] [Full Text] [Related]
20. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
Piedimonte S; Kim R; Bernardini MQ; Atenafu EG; Clark M; Lheureux S; May T
Gynecol Oncol; 2022 Dec; 167(3):417-422. PubMed ID: 37191644
[TBL] [Abstract] [Full Text] [Related]
[Next]
